GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » Inventory-to-Revenue

Aquestive Therapeutics (Aquestive Therapeutics) Inventory-to-Revenue : 0.60 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Aquestive Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2024 was $7.25 Mil. Aquestive Therapeutics's Revenue for the three months ended in Mar. 2024 was $12.05 Mil. Aquestive Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.60.

Aquestive Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 increased from Dec. 2023 (0.52) to Dec. 2023 (0.60)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Aquestive Therapeutics's Days Inventory for the three months ended in Mar. 2024 was 150.76.

Inventory Turnover measures how fast the company turns over its inventory within a year. Aquestive Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.61.


Aquestive Therapeutics Inventory-to-Revenue Historical Data

The historical data trend for Aquestive Therapeutics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aquestive Therapeutics Inventory-to-Revenue Chart

Aquestive Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory-to-Revenue
Get a 7-Day Free Trial 0.08 0.06 0.06 0.10 0.12

Aquestive Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.49 0.50 0.52 0.60

Competitive Comparison of Aquestive Therapeutics's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aquestive Therapeutics's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aquestive Therapeutics's Inventory-to-Revenue falls into.



Aquestive Therapeutics Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Aquestive Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (5.78 + 6.769) / 2 ) / 50.583
=6.2745 / 50.583
=0.12

Aquestive Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue (Q: Mar. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count ) / Revenue (Q: Mar. 2024 )
=( (6.769 + 7.734) / 2 ) / 12.053
=7.2515 / 12.053
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aquestive Therapeutics  (NAS:AQST) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Aquestive Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=7.2515/4.389*365 / 4
=150.76

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Aquestive Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=4.389 / 7.2515
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aquestive Therapeutics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Executives
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki officer: SVP, Research & Development C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung officer: SVP, Operations C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt officer: Chief Medical Officer C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris director ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd officer: SVP-Operations/Value Delivery 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender officer: SVP, General Counsel 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber officer: SVP-Chief Strategy/Dev Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel director, officer: Chief Innovation/Tech Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr officer: Interim CFO
John T. Maxwell officer: SVP-Chief Financial Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall director, officer: President and CEO 30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta director C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154

Aquestive Therapeutics (Aquestive Therapeutics) Headlines

From GuruFocus